Descartes-25 in Relapsed/Refractory Multiple Myeloma

Verified

Overview

This is a Phase I/IIa dose-escalation study to evaluate the safety, tolerability, and preliminary efficacy of an allogeneic Mesenchymal Stem Cell (Descartes-25) product secreting a bispecific protein and other proteins in patients with relapsed/refractory multiple myeloma.

SparkCures ID 1224
Trial Phase Phase 1/2
Enrollment 9 Patients
Treatments
Tags
  • RNA Cell Therapy (Allogeneic)
Trial Sponsors
  • Cartesian Therapeutics
NCT Identifier

NCT05113342

Am I Eligible?

The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.

The following criteria is provided for health care professionals.

Inclusion Criteria:

  • 18 years and older
  • Diagnosed with active R/RMM, who have failed 2 lines of treatment
  • Have measurable disease

Exclusion Criteria:

  • Patients with active plasma cell leukemia

US Trial Locations

Please visit the ClinicalTrials.gov page for historical site information.

View Centers

Trial Links

Read the latest news and updates on this trial.

SparkCures Verified

SparkCures is working closely with Cartesian Therapeutics to provide the most up-to-date information on this clinical trial. Use the button above to add this trial to your list of favorites.

Learn more about how we work with trial sponsors